Novartis is considering spinning off its $25 billion generics division
As a challenging environment for leveraged buyouts makes a prospective sale to private equity more challenging, Novartis AG is moving toward a spinoff of its generic pharmaceuticals unit, according to people familiar with the matter. The people, who asked not to be named because the information